Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > AGN.c has been granted Orphan Drug Designation to Ifenprodil

<< Previous

Bullboard Posts

Next >>

Post by stockpatrolon Dec 05, 2022 6:49pm

193 Views

Post# 35152211

AGN.c has been granted Orphan Drug Designation to Ifenprodil

AGN.c has been granted Orphan Drug Designation to Ifenprodil for treatment of Pulmonary fibrosis.

https://ca.finance.yahoo.com/news/algernon-pharmaceuticals-receives-u-fda-120000269.html

Recently completing phase 2 study on Ifenprodil in patients showed no worsening of lung function and significant improvements were seen.

. “This regulatory milestone comes at an important time in the development of Ifenprodil as a potential new therapy for IPF, as we plan the next steps for our clinical program.”

AGN.c looking strong closing up 22% today surpassing the $3 mark.

<< Previous

Bullboard Posts

Next >>

Gold, growth and sustainability in focus for Mandalay Resources